INMB
INmune Bio Soars in Q4 2025: Advancing CORDStrom and XPro Platforms with Promising Results
In a pivotal year for INmune Bio, the company has made significant strides in advancing its therapeutic platforms, yielding promising results that have sparked investor interest. The company's latest quarterly earnings call revealed a flurry of activity across its portfolio, with CORDStrom and XPro emerging as key drivers